Safety considerations: Discontinue if you experience persistent rash, itching, or allergic reaction at the application site Talk to your provider before use if pregnant, breastfeeding, on diabetes medications, or taking anticoagulants Seek medical attention for severe or systemic reactions Staying Safe in a Crowded GLP1 Patch Market The GLP-1 boom attracted both responsible brands and opportunistic products making aggressive promises
Time spent trying ineffective supplements instead of pursuing evidence-based medical care can allow conditions to progress unnecessarily

These findings are concordant with those of observational studies that have also observed a decreased risk of major adverse cardiovascular events when comparing the GLP-1 receptor agonist-SGLT-2 inhibitor combination with different types of comparators: sulfonylurea-GLP-1 receptor agonist combination (hazard ratio 0.67, 0.59 to 0.89),30 metformin-sulfonylurea combination (hazard ratio 0.53, 0.35 to 0.80),31 and other combination regimens (odds ratio 0.70, 0.50 to 0.98).19 As these studies compared the GLP-1 receptor agonist-SGLT2 inhibitor combination with other drug combinations, they were designed to answer different clinical questions.193031 By contrast, our study was specifically designed to determine whether the add-on of a GLP-1 receptor agonist or an SGLT-2 inhibitor versus either drug class alone results in additional benefits on cardiovascular and renal outcomes

Now the landscape is shifting rapidly with the widespread use of medications such as Semaglutide, Liraglutide, and Tirzepatide
Fight Against Autoimmune Disease Chronic inflammation due to autoimmune disease can elevate oxidative stress
Junker AE, Gluud L, Holst JJ, Knop FK, Vilsboll T (2016) Diabetic and nondiabetic patients with nonalcoholic fatty liver disease have an impaired incretin effect and fasting hyperglucagonaemia